Cytokinetics

Youtube Subscribe

Open: 37.79 Close: 38.95 Change: 1.16

You don't have read the whole internet to decide whether to invest in Cytokinetics. Use an AI.

Are looking for the most relevant information about Cytokinetics? Investor spend a lot of time searching for information to make investment decisions in Cytokinetics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Cytokinetics are: Cytokinetics, clinical, dose, company, Phase, study, first, and the most common words in the summary are: cytokinetics, company, incorporate, profile, stock, report, unlock, . One of the sentences in the summary was: Cytokinetics posted revenues of $4.61 million for the quarter ended March 2023, surpassing the …

Concept Map

Semantic Network

Stock Summary

Cytokinetics, Incorporated focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug.

Today's Summary

Cytokinetics posted revenues of $4.61 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 163.60% Company announced the CRL on Tuesday, as well as their intentions to forego any future clinical trials.

Today's News

Cytokinetics announces three upcoming presentations at the european society of cardiology heart.... The company has dosed the first subjects in a Phase I clinical trial of CK-4021586. Cytokinetics announces initiation of phase 1 clinical study of ck-4021586. First participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical study. Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company. The first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled clinical study. Cytokinetics posted revenues of $4.61 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 163.60%. Company announced the CRL on Tuesday, as well as their intentions to forego any future clinical trials. Recent reports indicate that several hedge funds have made significant changes to their positions in Cytokinetics. Despite recent changes in position from several key investors such as JP Morgan Chase & Co boosting their stake. Cytokinetics Incorporated (KK3A) is traded on Frankfurt Exchange in Germany and employs 253 people. Cytkinetics Inc. has accumulated about 176.62  M in cash with (142.52  M ) of positive cash flow from operations. The company has about a 20 % chance of experiencing some form of financial distress.

Stock Profile

"Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California."

Keywords

How much time have you spent trying to decide whether investing in Cytokinetics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Cytokinetics are: Cytokinetics, clinical, dose, company, Phase, study, first, and the most common words in the summary are: cytokinetics, company, incorporate, profile, stock, report, unlock, . One of the sentences in the summary was: Cytokinetics posted revenues of $4.61 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 163.60% Company announced the CRL on Tuesday, as well as their intentions to forego any future clinical trials.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #cytokinetics #company #incorporate #profile #stock #report #unlock.

Read more →

Youtube Subscribe

---